Dual Glucagon and GLP ‐1 Receptor Agonist Survodutide Improves Biomarkers of Beta‐Cell Function and Insulin Sensitivity in People With Type 2 Diabetes or Living With Overweight/Obesity
Authors' conclusion
Survodutide was associated with significantly improved beta-cell function and insulin sensitivity in adults with type 2 diabetes and with overweight or obesity. The durability of beta-cell improvements after treatment cessation remains unknown. These effects were largely independent of bodyweight changes, suggesting additional metabolic benefit beyond weight loss.
Study context
- Population
- Trial 1404–0002: T2D on metformin (16 weeks); trial 1404–0036: overweight/obesity and normoglycaemia (46 weeks)2 trials: 413 and 387 randomised
- Comparison
- Survodutide vs placebo
Primary result
As reported in the abstract
Beta-cell function, insulin sensitivity and glucose biomarkers
- Trial 1404-0002 (T2D): survodutide vs placebo significantly and rapidly increased HOMA-β, and significantly decreased HOMA-IR, glucagon and fasting plasma glucose (FPG)
- Trial 1404-0002: no significant changes in high-molecular-weight (HMW) adiponectin, C-peptide or fasting insulin
- Trial 1404-0036 (overweight/obesity): no significant change in HOMA-β with survodutide vs placebo, likely owing to normoglycaemia
- Trial 1404-0036: survodutide vs placebo significantly decreased HOMA-IR, glucagon, C-peptide, fasting insulin and FPG, and significantly increased HMW adiponectin
- Post hoc analysis
Further findings
Contribution of bodyweight change (all survodutide doses combined)
- Absolute bodyweight change explained the largest proportion of variability in changes in fasting insulin and HOMA-IR, but not the other changes observed
Original publication
Dual Glucagon and GLP ‐1 Receptor Agonist Survodutide Improves Biomarkers of Beta‐Cell Function and Insulin Sensitivity in People With Type 2 Diabetes or Living With Overweight/Obesity. Diabetes Obes Metab. Published 22 June 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →